Targeted deletion of PD-1 in myeloid cells induces antitumor immunity
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
mice, accumulation of GMP and MDSC was prevented, whereas systemic output of effector myeloid cells was increased. Myeloid cell-specific PD-1 ablation induced an increase of T effector memory cells with improved functionality and mediated antitumor protection despite preserved PD-1 expression in T cells. In PD-1-deficient myeloid progenitors, growth factors driving emergency myelopoiesis induced increased metabolic intermediates of glycolysis, pentose phosphate pathway, and TCA cycle but, most prominently, elevated cholesterol. Because cholesterol is required for differentiation of inflammatory macrophages and DC and promotes antigen-presenting function, our findings indicate that metabolic reprogramming of emergency myelopoiesis and differentiation of effector myeloid cells might be a key mechanism of antitumor immunity mediated by PD-1 blockade.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PD-1 can be expressed on some myeloid cells as well, and changes in the myeloid compartment could lead to an influx of inflammatory cells into various, distant tissues/organs and inciting organ damage”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Strauss et al., 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247 · cited 2×
“However, similar to its role in infections, PD-1 expression inversely correlates with M1 polarization and phagocytic potency of tumor-associated M (TAM) against tumor (7, 8).”
BackgroundActivation of a metabolic gene regulatory network downstream of mTOR complex 1
Düvel, K., Yecies, J. L., Menon, S., Raman, P., Lipovsky, A. I., Souza, A. L., Triantafellow, E., Ma, Q., Gorski, R., Cleaver, S., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.022 · Cited by 2,020
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL
Tontonoz, P., Nagy, L., Alvarez, J. G. A., Thomazy, V. A., & Evans, R. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81575-5 · Cited by 1,797 · cited 2×
“Myeloid-specific PD-1 ablation induces improved T cell functionality Previously, it was determined that monocyte/macrophage terminal differentiation is controlled by the combined actions of retinoid receptors and the nuclear receptor peroxisome proliferator–activated receptor (PPAR), which is regulated by cholester…”
BackgroundSubsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J.-I., Nagaraj, S., Collazo, M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Cited by
Items 101–200 of 459
Hu, H., Zakharov, P. N., Peterson, O. J., & Unanue, E. R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019743117 · Cited by 67
“Blockade/deletion of PD-1 expression on tumor-associated macrophage restored phagocytosis, induced metabolic reprogramming of the macrophages, increased T cell effector function, promoted antigen presentation, and increased the survival of mice bearing tumors (62, 63).”
BackgroundTheivanthiran, B., Yarla, N. S., Haykal, T., Nguyen, Y., Cao, L., Ferreira, M., Holtzhausen, A., Al-Rohil, R. N., Salama, A. K. S., Beasley, G. M., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq7019 · Cited by 65
Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms
Joseph, G. J., Johnson, D. B., & Johnson, R. W. (2023) · Journal of bone oncology · doi:10.1016/j.jbo.2023.100505 · Cited by 58
“Notably, PD-1 inhibits signaling pathways in myeloid cells that are important for T cell activation, suggesting that myeloid specific PD-1 blockade may subvert myeloid cell-mediated immunosuppression [124] (Fig.”
BackgroundImmune checkpoint inhibitors associated cardiovascular immune-related adverse events
Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55
The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells
Laba, S., Mallett, G., & Amarnath, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.022 · Cited by 57
Colligan, S. H., Amitrano, A. M., Zollo, R. A., Peresie, J., Kramer, E. D., Morreale, B. G., Barbi, J. J., Singh, P. K., Yu, H., Wang, J., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158661 · Cited by 56
“Our group and others have demonstrated that MDSC biogenesis occurs through a process of dysregulated hematopoiesis that originates with early myeloid progenitors, such as GMPs, in the BM (2, 18, 21).”
BackgroundImpact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer
Drobni, Z. D., Gongora, C. A., Taron, J., Suero‐Abreu, G. A., Karády, J., Gilman, H. K., Sama, S., Nikolaidou, S., Leeper, N., Merkely, B. P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007307 · Cited by 55
Zhang, K., Zakeri, A., Alban, T. J., Dong, J., Ta, H. M., Zalavadia, A. H., Branicky, A., Zhao, H., Jurić, I., Husic, H., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2023.113661 · Cited by 62
Immune cellular components and signaling pathways in the tumor microenvironment
Yenyuwadee, S., Aliazis, K., Wang, Q., Christofides, A., Shah, R., Patsoukis, N., & Boussiotis, V. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.004 · Cited by 55
Self-citationLei, Z., Tang, R., Yu, W., Mao, C., Xue, W., Shen, J., Yu, J., Wang, X., Qi, X., Wei, C., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.165544 · Cited by 55
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264327 · Cited by 53
Metabolic Reprogramming in the Tumor Microenvironment With Immunocytes and Immune Checkpoints
Xu, Y., He, L., Fu, Q., & Hu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759015 · Cited by 52
“demonstrated that PD-1 ablation assists emergency myelopoiesis and differentiation of effector myeloid cells to strengthen anti-tumor immunity by increasing intermediates of glycolysis, tricarboxylic acid cycle (TCA cycle), pentose phosphate pathway (PPP) and elevated cholesterol (39).”
BackgroundBriviesca, R. L., Cruz‐Bermúdez, A., Nadal, E., Insa, A., García-Campelo, R., Huidobro, G., Dómine, M., Majem, M., Rodríguez‐Abreu, D., Martínez‐Martí, A., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.491 · Cited by 54
Triantafyllou, E., Gudd, C. L. C., & Possamai, L. A. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-01019-7 · Cited by 55
“Evidence also indicates that PD1 and PDL1 can regulate the function of myeloid cells (for example, macrophages) in inflammatory pathologies, including cancer 25–31 .”
IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors
Nejad, E. B., Labrie, C., van Elsas, M. J., Kleinovink, J. W., Mittrücker, H., Franken, K. L. M. C., Heink, S., Korn, T., Arens, R., van Hall, T., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002460 · Cited by 51
Kim, M. J., & Ha, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.767466 · Cited by 54
“PD-1 also regulates the metabolism of myeloid cells (Strauss et al., 2020).”
BackgroundInfluentialKeenan, B. P., McCarthy, E. E., Ilano, A., Yang, H., Zhang, L., Allaire, K. M., Fan, Z., Li, T. Y., Lee, D. S., Sun, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111384 · Cited by 49
“to defects in phagocytosis, and impair effective anti-tumor immunity (Diskin et al., 2020; Gordon et al., 2017; Strauss et al., 2020).”
BackgroundResultMoreo, E., Jarit-Cabanillas, A., Robles‐Vera, I., Uranga, S., Guerrero, C., Gómez, A. B., Mata-Martínez, P., Minute, L., Araujo‐Voces, M., Felgueres, M. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41768-8 · Cited by 48
What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang, Q., Xie, B., Liu, S., Shi, Y., Tao, Y., Xiao, D., & Wang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.773168 · Cited by 51
Self-citationCai, H., Li, M., Deng, R., Wang, M., & Shi, Y. (2022) · Biomarker Research · doi:10.1186/s40364-022-00413-0 · Cited by 48
“In addition, an animal experiment found that PD-1 knockout on myeloid cells also has antitumor activity [23].”
BackgroundTong, J., Tan, Y., Ouyang, W., & Chang, H. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00636-5 · Cited by 47
Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting
Singanayagam, A., & Triantafyllou, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661182 · Cited by 48
Targeting the epigenome to reinvigorate T cells for cancer immunotherapy
Xiong, D., Zhang, L., & Sun, Z. (2023) · Military Medical Research · doi:10.1186/s40779-023-00496-2 · Cited by 51
“…T cell function and confer resistance to ICIs, characterized by high surface expression of inhibitory molecules, including PD-L1 for myeloid cells (i.e., TAMs, MDSCs) and CTLA-4 for Treg cells, along with suppressive cytokines including IL-10 and transforming growth factor-beta (TGF-β) [133, 134].”
BackgroundPost-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy
Lee, T.-A., Tsai, E.-Y., Liu, S.-H., Hung, S.-D. H., Chang, S., Chao, C.-H., Lai, Y., Yamaguchi, H., & Li, C. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2664 · Cited by 48
The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy
Damasio, M. P. S., Nascimento, C. S., de Andrade, L. M., de Oliveira, V. L., & Calzavara-Silva, C. E. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1021609 · Cited by 48
“suggested that a deletion of PD-1 in myeloid cells during differentiation to effector Antigen-Presenting Cells (APCs) might be a key mechanism by which PD-1 blockade mediates antitumor function by reprogramming T cell responses (43).”
BackgroundHypoimmunogenic human iPSCs expressing HLA-G, PD-L1, and PD-L2 evade innate and adaptive immunity
Tsuneyoshi, N., Hosoya, T., Takeno, Y., Saitoh, K., Murai, H., Amimoto, N., Tatsumi, R., Watanabe, S., Hasegawa, Y., Kikkawa, E., et al. (2024) · Stem cell research & therapeutics · doi:10.1186/s13287-024-03810-4 · Cited by 40
“Human PD-1 (hPD-1) expressed on innate immune cells including NK cells, macrophages, and granulocytes has been reported to contribute to the immune suppressive environment [53–55].”
BackgroundDavidov, V., Jensen, G. L., Mai, S., Chen, S., & Pan, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01842 · Cited by 47
Bringing Macrophages to the Frontline against Cancer: Current Immunotherapies Targeting Macrophages
Reis-Sobreiro, M., da Mota, A. T., Jardim, C., & Serre, K. (2021) · Cells · doi:10.3390/cells10092364 · Cited by 45
Targeting cholesterol metabolism in Cancer: From molecular mechanisms to therapeutic implications
Lu, J., Chen, S., Bai, X., Liao, M., Qiu, Y., Zheng, L., & Yu, H. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115907 · Cited by 44
Challenges and strategies associated with CAR-T cell therapy in blood malignancies
Liu, Z., Lei, W., Wang, H., Liu, X., & Fu, R. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00490-x · Cited by 45
“Specific ablation of PD-1 on bone marrow progenitor cells also enhances immunity and inhibits tumor cell proliferation [187].”
BackgroundWeathers, S.-P. S., Li, X., Zhu, H., Damania, A. V., Knafl, M., McKinley, B. A., Lin, H. Y., Harrison, R. A., Majd, N., O'Brien, B. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56930-7 · Cited by 52
“The bene fi t of the neoadjuvant PD-1 blockade is believed to be primarily driven by the re-activation of exhausted T cells and the possible modulation of the tumor microenvironment to in fl uence non-T cell populations 20,21 .”
Immunotherapy for Glioblastoma: Current State, Challenges, and Future Perspectives
Yang, M., Oh, I. Y., Mahanty, A., Jin, W., & Yoo, J. S. (2020) · Cancers · doi:10.3390/cancers12092334 · Cited by 46
“Recently, Strauss and colleagues conducted an exploratory study verifying that the expression of PD-1 in myeloid cells can restrain host immunity against cancers and, therefore, it could be also a good target of anti-PD-1 ICIs [102].”
BackgroundRelecom, A., Merhi, M., Inchakalody, V. P., Shahab Uddin, M. S., Rinchai, D., Bedognetti, D., & Dermime, S. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01872-3 · Cited by 44
“This allowed the maturation of myeloid precursors to proceed into effector macrophages and dendritic cells, thereby contributing to reorganize the myeloid composition of the TME into one contributing favorably to the immune response [175].”
BackgroundTumor-associated neutrophils: orchestrating cancer pathobiology and therapeutic resistance
Bui, T. M., Yalom, L. K., & Sumagin, R. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1954162 · Cited by 47
“It was found that ablation of PD-1 response on myeloid cells in PD-1fl/fl LysMCre, but not on T cells in PD-1fl/fl CD4Cre mice, altered the metabolic outputs of G-MDSCs and activated the cholesterol synthesis of these cells via activation of mTORC1 and the mevalonate pathway.”
InfluentialChemokine Receptor-Targeted Therapies: Special Case for CCR8
Moser, B. (2022) · Cancers · doi:10.3390/cancers14030511 · Cited by 43
“However, the mechanism of action of PD-1/PD-L1-specific antibodies may go well beyond CD8+ T cells and may include PD-1-expressing myeloid cells, as recently demonstrated in mouse tumor models [48].”
BackgroundRawal, S., Randhawa, V., Rizvi, S. H. M., Sachan, M., Wara, A. K., Pérez‐Cremades, D., Weisbrod, R. M., Hamburg, N. M., & Feinberg, M. W. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae102 · Cited by 42
Implications of metabolism-driven myeloid dysfunctions in cancer therapy
Strauss, L., Guarneri, V., Gennari, A., & Sica, A. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-00556-w · Cited by 43
“showed that immune checkpoints such as PD-1 suppress the differentiation of MPs to effector APCs and promote the expansion of MDSCs through metabolic reprogramming of myeloid precursors.(218) Metformin, a widely used drug in treating and curing type II diabetes, has been proven to reduce the incidence of cancers, redu…”
BackgroundSelf-citationSarsembayeva, A., Kienzl, M., Gruden, E., Ristić, D., Maitz, K. S., Valadez-Cosmes, P., Santiso, A., Hasenoehrl, C., Brčić, L., Lindenmann, J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997115 · Cited by 44
“with 250 mg of rat monoclonal antimouse PD-1 antibody (72) (clone 29F.”
Effects of PD-1 Signaling on Immunometabolic Reprogramming
Boussiotis, V. A., & Patsoukis, N. (2022) · Immunometabolism · doi:10.20900/immunometab20220007 · Cited by 41
“Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman GJ, Kuchroo VK, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.”
BackgroundInfluentialSelf-citationGestationally dependent immune organization at the maternal-fetal interface
Moore, A. R., Gonzalez, N. V., Plummer, K. A., Mitchel, O. R., Kaur, H., Rivera, M., Collica, B., Goldston, M., Filiz, F., Angelo, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111651 · Cited by 40
“Given the increasing interest in myeloid expression of checkpoint proteins (Strauss et al., 2020), we applied linear regression to further evaluate lineage markers and PD-L1 expression”
MethodLi, M., Cui, Y., Qi, Q., Liu, J., Li, J., Huang, G., Yang, J., Sun, J., Ma, Z., Liang, S., et al. (2024) · Theranostics · doi:10.7150/thno.101575 · Cited by 40
Myeloid effector cells in cancer
Schol, P. J., van Elsas, M. J., Middelburg, J., Twilhaar, M. K. N., van Hall, T., van der Sluis, T. C., & van der Burg, S. H. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.11.002 · Cited by 41
Phadke, M. S., Chen, Z., Li, J., Mohamed, E. T., Davies, M. A., Smalley, I., Duckett, D. R., Palve, V. C., Czerniecki, B. J., Forsyth, P. A., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0905 · Cited by 54
“Recent work has shown that PD1, in addition to being expressed on activated/exhausted T cells, is also found on myeloid cells (43, 44).”
BackgroundWang, Q., Bardhan, K., Boussiotis, V. A., & Patsoukis, N. (2021) · Advanced Biology · doi:10.1002/adbi.202100758 · Cited by 39
Self-citationKim, J. E., Lee, R. P., Yazigi, E., Atta, L., Feghali, J., Pant, A., Jain, A., Levitan, I., Kim, E. S., Patel, K. K., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.12.007 · Cited by 40
“Cg-Tg(Cd4-cre)1Cwi/BfluJ), all of which were kindly provided by Dr. Vassiliki Boussiotis, Harvard Medical School (Boston, MA) (Strauss et al., 2020).”
BackgroundMethodResultSelf-citationAntigen presenting cells in cancer immunity and mediation of immune checkpoint blockade
Wang, C., Chen, L., Fu, D., Liu, W., Puri, A., Kellis, M., & Yang, J. (2024) · Clinical & Experimental Metastasis · doi:10.1007/s10585-023-10257-z · Cited by 39
“To solidify the direct effect of the PD-1 antagonist on myeloid cells, the same study treated T and B cell deficient mice with anti-PD-1 and found a significant reduction in tumor growth [66].”
BackgroundRajasekaran, N., Wang, X., Ravindranathan, S., Chin, D. J., Tseng, S.-Y., Klakamp, S. L., Widmann, K., Kapoor, V. N., Vexler, V. S., Keegan, P., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03635-3 · Cited by 39
“…with macrophage activation in DTCs. Myeloid cells have long been noted to contribute to the formation of an immunosuppressive tumor promoting niche in the TME [44] and myeloid-specific PD-1 targeting could mediate myeloid cell–intrinsic effects that initiate systemic anti-tumor responses.”
BackgroundGallucci, G., Turazza, F. M., Inno, A., Canale, M. L., Silvestris, N., Farì, R., Navazio, A., Pinto, C., & Tarantini, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084232 · Cited by 41
“Preclinical studies have shown that the targets of ICIs [PD-1 (programmed cell death protein 1), PD-L1 (programmed death ligand 1), CTLA-4 (cytotoxic T-lymphocyte– associated protein4)] are proteins with a negative regulatory role in atherosclerosis [135].”
BackgroundRemodeling tumor-associated macrophages in the tumor microenvironment
Chen, S., Li, S., & Wang, H. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000063 · Cited by 42
MDSC: a new potential breakthrough in CAR-T therapy for solid tumors
Abdalsalam, N. M. F., Ibrahim, A., Saliu, M. A., Liu, T., Wan, X., & Yan, D. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01995-y · Cited by 41
Xing, Z., Zuo, Z., Hu, D., Zheng, X., Wang, X., Yuan, L., Zhou, L., Qi, F., & Yao, Z. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.09.015 · Cited by 39
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Kuske, M., Haist, M., Jung, T., Grabbe, S., & Bros, M. (2022) · Cancers · doi:10.3390/cancers14071710 · Cited by 39
Steenbrugge, J., Bellemans, J., Elst, N. V., Demeyere, K., Vliegher, J. D., Perera, T. P. S., Wever, O. D., Broeck, W. V. D., Spiegelaere, W. D., Sanders, N. N., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2103277 · Cited by 39
“More specifically, deletion of PD-1 positivity on MDSCs and macrophages is known to mediate metabolic reprogramming that stimulates anti-tumor immunity and reduces myelopoiesis, necessary for ICB efficacy.(51)”
BackgroundVinnakota, J. M., Adams, R. C., Athanassopoulos, D., Schmidt, D., Biavasco, F., Zähringer, A., Erny, D., Schwabenland, M., Langenbach, M., Wenger, V., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj9672 · Cited by 41
“Our observation that anti–PD-1 directly activates microglia is consistent with a previous report showing that PD-1 deficiency in myeloid cells leads to their activation ( 40 ).”
BackgroundResultHill, C. N., Hernández‐Cáceres, M. P., Asencio, C., Torres, B. M., Solis, B., & Owen, G. I. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.605314 · Cited by 40
Chiang, C., Chiang, C., Sheng‐Kai, K., Hsia, Y. P., Lee, Y.-W., Wu, H., Chiang, C., Peng, C.-Y., Wei, J. C., Shiah, H., et al. (2022) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyac150 · Cited by 39
Cell Intrinsic and Systemic Metabolism in Tumor Immunity and Immunotherapy
Coleman, M. F., Cozzo, A. J., Pfeil, A. J., Etigunta, S. K., & Hursting, S. D. (2020) · Cancers · doi:10.3390/cancers12040852 · Cited by 39
Ghosh, S., Dutta, R., Ghatak, D., Goswami, D., & De, R. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.150268 · Cited by 36
Zhang, Y., Yuan, T., Li, Z., Luo, C., Wu, Y., Zhang, J., Zhang, X., & Fan, W. (2021) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.1c00081 · Cited by 36
TGF-β Alters the Proportion of Infiltrating Immune Cells in a Pancreatic Ductal Adenocarcinoma
Trebska-McGowan, K., Chaib, M., Alvarez, M. A., Kansal, R. G., Pingili, A. K., Shibata, D., Makowski, L., & Glazer, E. S. (2021) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-021-05087-x · Cited by 39
“Recent work by Strauss et al demonstrated that selective deletion of PD-L1 from TAMs and M-MDSCs differentiated to TAMs resulted in enhanced anti-tumor immune activity.(59)”
ResultMultimodal neuro-nanotechnology: Challenging the existing paradigm in glioblastoma therapy
Kudruk, S., Forsyth, C. M., Dion, M. Z., Orbeck, J., Luo, J. R., Klein, R. S., Kim, A. H., Heimberger, A. B., Mirkin, C. A., Stegh, A. H., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2306973121 · Cited by 38
“Since PD - 1 is also expressed in tumor - associated myeloid cells, including MDSCs, tumor - associated macrophages, and dendritic cells, myeloid - specific PD - 1 inhibition further augments anti - tumor immunity despite sustained PD - 1 expression in T cells (91).”
BackgroundClinical Relevance of CD4 Cytotoxic T Cells in High-Risk Neuroblastoma
Tang, X. X., Shimada, H., & Ikegaki, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.650427 · Cited by 35
Pant, A., Bergsneider, B. H.-L., Srivastava, S., Kim, T., Jain, A., Bom, S., Shah, P. P., Kannapadi, N. V., Patel, K. K., Choi, J. H., et al. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2338965 · Cited by 35
“As the role of PD-1 on lymphocytes and myeloid cells is an area of active interest in tumor immunology, 37,38 future studies looking at the combined lymphoid-and myeloid-specific effects of both CCR2/CCR5 blockade and checkpoint blockade (such as anti-PD-1 or anti-TIM-3, based on increase in TIM-3…”
BackgroundEmergency myelopoiesis in solid cancers
Aliazis, K., Yenyuwadee, S., Phikulsod, P., & Boussiotis, V. A. (2024) · British Journal of Haematology · doi:10.1111/bjh.19656 · Cited by 36
“97 Moreover, PD-1 induced the recruitment of SHP-2 to the GM-CSFR βc, a subunit shared by GM-CSF, IL-3, and IL-5 receptors, leading to impaired GM- CSF-mediated phosphorylation of IRF-8, 98 which is required for its transcriptional activation and differentiation of myeloid progenitors towards…”
Self-citationZhao, M., Zhou, L., Zhang, Q., Wang, M., Dong, Y., Wang, Y., Pei, R., He, E., Liang, Y., Shen, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202407900 · Cited by 38
Li, A., Chang, Y., Song, N., Wu, X., Chung, D., Riesenberg, B., Velegraki, M., Giuliani, G. D., Das, K., Okimoto, T., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005433 · Cited by 35
Chaudhri, A., Bu, X., Wang, Y., Gomez, M., Torchia, J. A., Hua, P., Hung, S.-H., Davies, M. A., Lizee, G. A., von Andrian, U. H., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1237715 · Cited by 35
“Response to anti-PD-1 therapy is associated with a higher mature myeloid fraction, and a lower immature myeloid cell fraction (57).”
BackgroundSingle-cell spatial transcriptomics reveals immunotherapy-driven bone marrow niche remodeling in AML
Gui, G., Bingham, M. A., Herzog, J. R., Wong-Rolle, A., Dillon, L. W., Goswami, M., Martin, E., Reeves, J., Kim, S. T., Bahrami, A. J., et al. (2025) · Science Advances · doi:10.1126/sciadv.adw4871 · Cited by 35
“Studies in mice have found that anti–PD-1 promotion can catalyze myeloid progenitors to differentiate into antitumor effector cells ( 27 ).”
Zhang, B., Hu, M., Ma, Q., Li, K., Li, X., He, X., Shu, P., Chen, Y., Gao, G., Qin, D., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.04.008 · Cited by 32
Functional crosstalk between T cells and monocytes in cancer and atherosclerosis
Padgett, L. E., Araujo, D. J., Hedrick, C. C., & Olingy, C. E. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.1mir0420-076r · Cited by 36
Innate Immune Cells in Melanoma: Implications for Immunotherapy
Trocchia, M., Ventrici, A., Modestino, L., Cristinziano, L., Ferrara, A. L., Palestra, F., Loffredo, S., Capone, M., Madonna, G., Romanelli, M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158523 · Cited by 33
“Indeed, in a graft model of murine melanoma, myeloid-cell-specific PD-1 ablation boosted the functionality of T effector cells, providing antitumor protection [168].”
BackgroundZhang, X., Chen, D.-G., Li, S. C., Zhu, B., & Li, Z. (2021) · Cells · doi:10.3390/cells10040903 · Cited by 32
Minegishi, S., Kinguchi, S., Horita, N., Namkoong, H., Briasoulis, Α., Ishigami, T., Tamura, K., Nishiyama, A., Yano, Y., & Japanese Society of Hypertension working group “Onco-Hypertension” (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19865 · Cited by 32
Lee, H., Ferguson, A. L., Quek, C. Y. J., Vergara, I. A., da Silva, I. P., Allen, R. O., Gide, T. N., Conway, J. W., Koufariotis, L. T., Hayward, N. K., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2657 · Cited by 32
Myeloid-derived suppressor cells deficient in cholesterol biosynthesis promote tumor immune evasion
Chen, Y., Xu, Y., Zhao, H., Zhou, Y., Zhang, J., Lei, J., Wu, L., Zhou, M., Wang, J., Yang, S., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216208 · Cited by 31
PD-1 receptor deficiency enhances CD30+ Treg cell function in melanoma
Lim, J. X., McTaggart, T., Jung, S. K., Smith, K. J., Hulme, G., Laba, S., Ng, Y. Q., Williams, A., Hussain, R., Coxhead, J., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02172-0 · Cited by 32
Wu, B., Chiang, H.-C., Sun, X., Yuan, B., Mitra, P., Hu, Y., Curiel, T. J., & Li, R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000964 · Cited by 33
Liu, Y., Xu, C., Zhang, L., Xu, G., Yang, Z., Xiang, L., Jiao, K., Chen, Z., Zhang, X., & Liu, Y. (2024) · Science Advances · doi:10.1126/sciadv.adi7764 · Cited by 31
“…mechanisms include the poor accumulation and dysfunction of antitumor immune cells ( 14 , 15 ), the increased infiltration and inhibitory function of immunosuppressive cells ( 5 , 15 , 16 ), abnormal vasculature ( 17 ), metabolic status ( 18 , 19 ), and other biological events ( 20 ).”
BackgroundImmune microenvironment of tumor-draining lymph nodes: insights for immunotherapy
Wei, J., Li, D., Long, H., & Han, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1562797 · Cited by 33
“However, during tumor progression, DCs undergo a functional shift from immune activation to immune suppression (54 – 56).”
Dendritic cells: understanding ontogeny, subsets, functions, and their clinical applications
Li, W., Yu, C., Zhang, X., Gu, Y., He, X., Xu, R., Xu, J. F., Yu, G., & Wu, Y. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00300-8 · Cited by 30
“In PD-1-deficient models, elevated mitochondrial metabolites like cholesterol drive DCs inflammatory polarization and antigen presentation [400, 409], supporting combined acetyl-CoA modulation with DCs vaccines to potentiate immune checkpoint inhibition.”
Advances in immune checkpoint inhibitors induced-cardiotoxicity
Li, X., Peng, W., Wu, J., Yeung, S. J., & Yang, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1130438 · Cited by 30
“Frontiers in Immunology 04 bone marrow progenitor cells up-regulate genes involved in cholesterol synthesis and ingestion, leading to elevated cholesterol (73).”
BackgroundDeciphering the roles of myeloid derived suppressor cells in viral oncogenesis
Glover, A. W., Zhang, Z., & Shannon-Lowe, C. D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1161848 · Cited by 29
“However, maintenance and accumulation of the M-MDSC population appears to be mediated, at least in part, by PD-1 and TNF signalling respectively, whereby PD1-deletion in a murine model appears to prevent M-MDSC accumulation (43) and TNF signalling through TNFR-2 appears to prevent M-MDSC apoptosis in a cFLIP-dependent…”
BackgroundLipid metabolism and tumor immunotherapy
Wang, Y., Guo, Z., Danbala, I. A., Chen, S., Ren, Y., & Cai, H. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1187989 · Cited by 30
“, 2017) and promotes cell antigen-presenting function (Anderson and Roche, 2015), which may be the critical mechanism by which PD-1 blocks cell cycle progression and induces antitumour effects (Strauss et al., 2020).”
BackgroundCD8 cis-targeted IL-2 drives potent antiviral activity against hepatitis B virus
Andreata, F., Moynihan, K. D., Fumagalli, V., Lucia, P. D., Pappas, D. C., Kawashima, K., Ni, I., Bessette, P. H., Perucchini, C., Bono, E. B., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adi1572 · Cited by 31
“However, PD-1 is not selective for CD8 + T cells, given that expression by innate and myeloid cell types has been observed ( 40 , 41 ).”
BackgroundAndreou, C., Plakas, K., Berisha, N., Gigoux, M., Rosch, L. E., Mirsafavi, R., Oseledchyk, A., Pal, S., Zamarin, D., Merghoub, T., et al. (2022) · Nanoscale Horizons · doi:10.1039/d2nh00331g · Cited by 28
Huang, S., Kang, Y., Liu, T., Xiong, Y., Yang, Z., & Zhang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561968 · Cited by 30
“…models have shown that myeloid cells that are de fi cient in the expression of PD-1, promote the genes implicated in cholesterol synthesis and attenuate the genes involved metabolism of cholesterol, thus amplifying cholesterol levels, which is an established determinant of atherosclerosis (128).”
Immune Checkpoint Inhibitors and Cardiovascular Adverse Events
Perna, M. L. D., Rigamonti, E., Zannoni, R., Espeli, V. G., & Moschovitis, G. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15281 · Cited by 28
Riva, M., Wouters, R., Sterpin, E., Giovannoni, R., Boon, L., Himmelreich, U., Gsell, W., Ranst, M. A. V., & Coosemans, A. (2020) · Neurosurgery · doi:10.1093/neuros/nyaa421 · Cited by 30
Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy
Cuyàs, E., Verdura, S., Martín-Castillo, B., Alarcón, T., Lupu, R., Bosch‐Barrera, J., & Menéndez, J. A. (2020) · Cancers · doi:10.3390/cancers12071757 · Cited by 30
Hernández, I., Rodeiro, I., Declerck, K., Herrera, J., Perez-Novo, C. A., Camp, G. V., Wever, O. D., González, K., Labrada, M., Carr, A., et al. (2021) · Marine Drugs · doi:10.3390/md19020052 · Cited by 26
“For example, targeted deletion of PD-1 in myeloid cells was already shown to induce antitumor immunity [52].”
BackgroundPD-L1 regulates inflammatory programs of macrophages from human pluripotent stem cells
Cao, H., Xiang, Y., Zhang, S., Chao, Y., Guo, J., Aurich, T., Ho, J. W. K., Huang, Y., Liu, P., & Sugimura, R. (2023) · Life Science Alliance · doi:10.26508/lsa.202302461 · Cited by 26
Wang, Y., Cho, J.-W., Kastrunes, G. M., Buck, A., Razimbaud, C., Culhane, A. C., Sun, J., Braun, D. A., Choueiri, T. K., Wu, C. J., et al. (2024) · iScience · doi:10.1016/j.isci.2024.108879 · Cited by 28
“89 Moreover,deletionofPDCD1hasbeenreportedtoimpairTcellsurvival,memory development,andfunction.”
Cheng, Y., Han, X., Lai, X., & Wei, X. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156093 · Cited by 25
Toghraie, F. S., Bayat, M., Hosseini, M. S., & Ramezani, A. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01051-y · Cited by 25
Krueger, J., Santinon, F., Kazanova, A., Issa, M. E., Larrivée, B., Kremer, R. B., Milhalcioiu, C., & Rudd, C. E. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251731 · Cited by 25
“Anti-PD-1 therapy showed a trend in decreasing the presence of suppressive M-MDSCs (Fig 1L) and PMN-MDSCs (Fig 1M) as well as in increasing the ratio of M-MDSCs to PMN-MDSCs (Fig 1N), as reported [48].”
BackgroundResultKUMAGAI, Y., Futoh, Y., Miyato, H., Ohzawa, H., Yamaguchi, H., Saito, S., Kurashina, K., Hosoya, Y., Lefor, A. K., Sata, N., et al. (2022) · In Vivo · doi:10.21873/invivo.12811 · Cited by 25
Neoantigen vaccination augments antitumor effects of anti-PD-1 on mouse hepatocellular carcinoma
Yang, S., Weng, M., Liang, J., Chiou, L., Hsu, Y.-C., Lee, Y.-T., Liu, S.-Y., Wu, M.-C., Chou, H.-C., Wang, L., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216192 · Cited by 28
Jin, J., Zhao, Q., Wei, Z., Chen, K., Su, Y., Hu, X., & Peng, X. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01138-9 · Cited by 25
“On the other hand, exogenous cholesterol accumulation could prevent DCs glycolysis, thereby further decreasing the ingredient acetyl-CoA in cholesterol replenish synthesis, as well as hindering DCs migration and antigen presenting ability [30, 68].”
BackgroundLin, X., Xie, M., Yao, J., Ma, X., Lin, Q., Zhang, X., Song, J., Bao, X., Zhang, X., Zhang, Y., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1613 · Cited by 25
“108,109 Anti-PD-1 therapy can induce alterations within the myeloid compartment, leading to a systemic accumulation of inflammatory cells across various organs and tissues.”
BackgroundNon-canonical PD-1 signaling in cancer and its potential implications in clinic
Zha, H., Jiang, Y., Wang, X., Shang, J., Wang, N., Yu, L., Zhao, W., Li, Z., Zhang, X., Zhang, X., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001230 · Cited by 25
Metadata
- Authors
- Strauss, L., Mahmoud, M. A. A., Weaver, J. D., Tijaro-Ovalle, N. M., Christofides, A., Wang, Q., Pal, R., Yuan, M., Asara, J., Patsoukis, N., & Boussiotis, V. A.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Boussiotis, Vassiliki A.
- ORCID
- Venue
- Science Immunology
- Published
- 2020-01-03
- Volume
- 5
- Issue
- 43
- ISSN
- 2470-9468 (ISSN-L)
- PMC
- PMC7183328
- OpenAlex
- W2997277554
- Cited by
- 437
- References
- 73
- Citations by year
- 2026: 30 · 2025: 51 · 2024: 67 · 2023: 83 · 2022: 70 · 2021: 77 · 2020: 59
- FWCI
- 26.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA183605, P01CA142106, R01CA212605)
- National Institute of Allergy and Infectious Diseases (R56AI098129)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R21AR073494)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, myeloid cells, antitumor immunity, myeloid-derived suppressor cells, good manufacturing practices, emergency myelopoiesis, myeloid progenitor cells, cholesterol metabolism, metabolic reprogramming, macrophage differentiation, dendritic cell differentiation, anti-PD-1 therapy, tumor immunology
- MeSH terms
- Animals, Cell Differentiation, Colonic Neoplasms, Female, Male, Melanoma, Mice, Inbred C57BL, Mice, Transgenic, Myeloid Cells, Cell Line, Tumor, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.